Sagimet Biosciences Inc Series A (SGMT) Stock Price, Quote & News - Mboum

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 561 8600

Website: www.sagimet.com

Address:

155 Bovet Road, Suite 303, San Mateo, United States

AnyaGirl Aug. 1 at 11:33 PM

Oh God not the after market/pre market pump, always leads to a dump after $SGMT

0 · Reply

gheko Aug. 1 at 6:22 PM

$SGMT everyone is panicking , always remember this is a bullish stock recently about positive news, just wait and your patience being rewarded..🎅

1 · Reply

John___wick44 Aug. 1 at 5:57 PM

$SGMT no sugar coating a down 25 percent week and market has not really corrected at all.

1 · Reply

John___wick44 Aug. 1 at 5:43 PM

$SGMT no news for 9-10 months. could easily retrace to 4-5

0 · Reply

John___wick44 Aug. 1 at 5:33 PM

$SGMT take out a 100 m in cash company valued at roughly 150m. seems outrageous

0 · Reply

LakeAccess Aug. 1 at 5:20 PM

$SGMT Long on this - love the novel MOA, molecule, management, and BoD - hate seeing the drop but am used to it and want to see how the story ends. I wish I was smarter on trading a portion of shares but FOMO always kicks in. They should have oncology combo therapy (with Roche) P3 data (run by partner in China) in 4Q25 so that will be some news coming. I am very curious what the data will look like. I got in this a while ago so even at these levels more than 100% unrealized gain - can afford to watch the end of the movie. The real story and money is in MASH and, if/when they announce how a monotherapy can get funded (without dilution - at these price levels not as likely thank heavens) this thing will light up to the moon. Good oncology data will give it a pop and provide more evidence to the diversity of the molecule - but MASH is where it’s at.

1 · Reply

John___wick44 Aug. 1 at 4:46 PM

$SGMT there drug works and is amazing. 38 BO minimum. more like 50-60

2 · Reply

John___wick44 Aug. 1 at 4:11 PM

$SGMT looks like it wants to hit the 7’s today.

0 · Reply

DonkeyPuncherDude Aug. 1 at 3:37 PM

$SGMT If you are holding and didn’t take profits at $11, you a dang fool. Just look at the volume over the past week or so and no pending news in the near term. Puts are printing 💰 Bullish long term. Bearish short term.

3 · Reply

Norny44 Aug. 1 at 3:08 PM

$SGMT oh dear 😳. I'm sure it will recover soon enough 🤷‍♂️

0 · Reply

Latest News on SGMT

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 9, 2025, 7:00 AM EDT - 7 weeks ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Jun 4, 2025, 1:45 PM EDT - 2 months ago

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Jun 4, 2025, 5:00 AM EDT - 2 months ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 22, 2025, 8:00 AM EDT - 2 months ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 6:00 AM EDT - 3 months ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 5 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 11, 2025, 8:00 AM EDT - 5 months ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Mar 7, 2025, 4:27 PM EST - 5 months ago

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 14, 2024, 3:56 PM EST - 9 months ago

Sagimet: More Than Just A MASH Drug Development Biotech

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Nov 12, 2024, 6:30 AM EST - 9 months ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 18, 2024, 3:10 PM EDT - 10 months ago

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 11, 2024, 7:00 AM EDT - 10 months ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 7:00 AM EDT - 10 months ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2024, 12:05 AM EDT - 10 months ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sep 12, 2024, 7:30 AM EDT - 11 months ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jul 31, 2024, 12:24 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Jun 6, 2024, 5:00 AM EDT - 1 year ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 16, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 7, 2024, 8:00 AM EDT - 1 year ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

May 6, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 26, 2024, 12:23 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Mar 25, 2024, 6:15 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Feb 29, 2024, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Jan 25, 2024, 8:58 PM EST - 1 year ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 24, 2024, 1:55 PM EST - 1 year ago

Sagimet: Additional Upside Possible After Latest NASH Data Release

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Jan 23, 2024, 5:45 PM EST - 1 year ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 11:10 PM EST - 1 year ago

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 7:00 AM EST - 1 year ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Dec 4, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Nov 28, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 22, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 13, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Nov 10, 2023, 8:30 AM EST - 1 year ago

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

Oct 24, 2023, 11:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Oct 18, 2023, 4:05 PM EDT - 1 year ago

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sep 27, 2023, 4:05 PM EDT - 2 years ago

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Sep 27, 2023, 2:48 PM EDT - 2 years ago

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 21, 2023, 4:02 PM EDT - 2 years ago

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

Aug 15, 2023, 4:04 PM EDT - 2 years ago

Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

Sagimet Biosciences Announces Leadership Changes

Jul 20, 2023, 4:05 PM EDT - 2 years ago

Sagimet Biosciences Announces Leadership Changes

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

Jul 15, 2023, 3:28 AM EDT - 2 years ago

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

APGE ODD OPHV SRFM TURB

Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering

Jul 13, 2023, 9:10 PM EDT - 2 years ago

Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering

IPO Update: Sagimet Biosciences Pushes Forward On IPO Plan

Jul 11, 2023, 5:41 PM EDT - 2 years ago

IPO Update: Sagimet Biosciences Pushes Forward On IPO Plan

Sagimet Biosciences sets IPO terms, to raise up to about $80 million

Jul 10, 2023, 7:05 AM EDT - 2 years ago

Sagimet Biosciences sets IPO terms, to raise up to about $80 million

AnyaGirl Aug. 1 at 11:33 PM

Oh God not the after market/pre market pump, always leads to a dump after $SGMT

0 · Reply

gheko Aug. 1 at 6:22 PM

$SGMT everyone is panicking , always remember this is a bullish stock recently about positive news, just wait and your patience being rewarded..🎅

1 · Reply

John___wick44 Aug. 1 at 5:57 PM

$SGMT no sugar coating a down 25 percent week and market has not really corrected at all.

1 · Reply

John___wick44 Aug. 1 at 5:43 PM

$SGMT no news for 9-10 months. could easily retrace to 4-5

0 · Reply

John___wick44 Aug. 1 at 5:33 PM

$SGMT take out a 100 m in cash company valued at roughly 150m. seems outrageous

0 · Reply

LakeAccess Aug. 1 at 5:20 PM

$SGMT Long on this - love the novel MOA, molecule, management, and BoD - hate seeing the drop but am used to it and want to see how the story ends. I wish I was smarter on trading a portion of shares but FOMO always kicks in. They should have oncology combo therapy (with Roche) P3 data (run by partner in China) in 4Q25 so that will be some news coming. I am very curious what the data will look like. I got in this a while ago so even at these levels more than 100% unrealized gain - can afford to watch the end of the movie. The real story and money is in MASH and, if/when they announce how a monotherapy can get funded (without dilution - at these price levels not as likely thank heavens) this thing will light up to the moon. Good oncology data will give it a pop and provide more evidence to the diversity of the molecule - but MASH is where it’s at.

1 · Reply

John___wick44 Aug. 1 at 4:46 PM

$SGMT there drug works and is amazing. 38 BO minimum. more like 50-60

2 · Reply

John___wick44 Aug. 1 at 4:11 PM

$SGMT looks like it wants to hit the 7’s today.

0 · Reply

DonkeyPuncherDude Aug. 1 at 3:37 PM

$SGMT If you are holding and didn’t take profits at $11, you a dang fool. Just look at the volume over the past week or so and no pending news in the near term. Puts are printing 💰 Bullish long term. Bearish short term.

3 · Reply

Norny44 Aug. 1 at 3:08 PM

$SGMT oh dear 😳. I'm sure it will recover soon enough 🤷‍♂️

0 · Reply

AnyaGirl Aug. 1 at 2:53 PM

$SGMT market up? dumps market down? dumps market recovering? dumps more

0 · Reply

AnyaGirl Aug. 1 at 2:07 PM

$SGMT were complete fools for not selling at 11+

0 · Reply

swedishben Aug. 1 at 12:24 PM

$SGMT Stay Green

1 · Reply

Norny44 Aug. 1 at 10:31 AM

$SGMT 7's or back up to 9's?🤔

1 · Reply

AnyaGirl Jul. 31 at 6:20 PM

$SGMT This is what i deserve for not selling at 11+

1 · Reply

AnyaGirl Jul. 31 at 2:11 PM

$SGMT Oh no… who couldnt see this coming

1 · Reply

John___wick44 Jul. 31 at 2:08 PM

$SGMT still seeing it drift back to 7 range over the next 3 months.

0 · Reply

AnyaGirl Jul. 31 at 1:03 PM

$SGMT probably 9$ at oprn then dump all day to 8.2

2 · Reply

AnyaGirl Jul. 31 at 11:03 AM

$SGMT Hard days watching everything skyrocket but being stuck in this like an idiot

0 · Reply

Norny44 Jul. 30 at 8:26 PM

$SGMT Next news being the optimist could be within the next month and it will be a big one

1 · Reply

cwgray10 Jul. 30 at 7:44 PM

0 · Reply

John___wick44 Jul. 30 at 7:05 PM

$SGMT 15% clip in two days

2 · Reply